Literature DB >> 20585009

Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction.

Denise Hilfiker-Kleiner1, Praphulla Shukla, Gunnar Klein, Arnd Schaefer, Britta Stapel, Melanie Hoch, Werner Müller, Michaela Scherr, Gregor Theilmeier, Matthias Ernst, Andres Hilfiker, Helmut Drexler.   

Abstract

BACKGROUND: In patients with myocardial infarction, high serum levels of interleukin-6 cytokines predict a poor outcome. The common receptor of interleukin-6 cytokines, glycoprotein-130 (gp130), signals via janus kinase/signal transducer and activator of transcription (STAT), cytoplasmic protein tyrosine phosphatase/extracellular signal-regulated kinase, and phosphoinositide-3-kinase/Akt pathways, and the regulation of these pathways depends at least in part on the gp130 tyrosine-757 residue. By analyzing cardiomyocyte-specific gp130(Y757F) mutant mice, we investigated the effect of disturbed gp130 signaling after myocardial infarction. METHODS AND
RESULTS: The cardiomyocyte-restricted alpha-myosin heavy chain-Cre-recombinase-loxP system was used to generate mice with gp130(Y757F) mutant cardiomyocytes (alphaMHC-Cre(tg/-);gp130(fl/Y757F) [Y(757)F]); all other cells carried at least 1 functional gp130 gene, ensuring normal gp130 signaling. Y(757)F mice displayed normal cardiac function and morphology at 3 months of age comparable to their nonmutant littermates. In response to myocardial infarction, Y(757)F mice displayed higher mortality associated with increased left ventricular rupture rate, sustained cardiac inflammation, and heart failure. These adverse effects were associated with prolonged and enhanced STAT3 activation and increased expression of interleukin-6 and of the complement-activating mannose-binding lectin C. Pharmacological inhibition of the complement system by cobra venom factor attenuated inflammation, prevented left ventricular rupture, and improved cardiac function in Y(757)F mice. Stronger effects were observed with a genetic reduction of STAT3 (STAT3(flox/+)) restricted to cardiomyocytes in Y(757)F mice, which prevented extensive upregulation of interleukin-6, complement activation, and sustained inflammation and lowered left ventricular rupture rate, heart failure, and mortality in subacute myocardial infarction.
CONCLUSIONS: Impaired downregulation of gp130-mediated STAT3 activation in subacute infarction promotes cardiac inflammation, adverse remodeling, and heart failure, suggesting a potential causative role of high interleukin-6 serum levels after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585009     DOI: 10.1161/CIRCULATIONAHA.109.933127

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  67 in total

1.  Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation.

Authors:  Angela S Pechenino; Li Lin; Fiona N Mbai; Alison R Lee; Xian-Min He; John N Stallone; A A Knowlton
Journal:  Physiol Genomics       Date:  2011-07-12       Impact factor: 3.107

2.  STAT3 integrates cytokine and neurotrophin signals to promote sympathetic axon regeneration.

Authors:  Michael J Pellegrino; Beth A Habecker
Journal:  Mol Cell Neurosci       Date:  2013-07-03       Impact factor: 4.314

Review 3.  Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction.

Authors:  Mingyuan Huang; Du Yang; Meixiang Xiang; Jianan Wang
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

Review 4.  Enzymes and signal pathways in the pathogenesis of alcoholic cardiomyopathy.

Authors:  E Leibing; T Meyer
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

5.  Opposing actions of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) in regulating microtubule stabilization during cardiac hypertrophy.

Authors:  Dominic C H Ng; Ivan H W Ng; Yvonne Y C Yeap; Bahareh Badrian; Tatiana Tsoutsman; Julie R McMullen; Christopher Semsarian; Marie A Bogoyevitch
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

6.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Authors:  James T Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M Bengel; Denise Hilfiker-Kleiner
Journal:  JCI Insight       Date:  2017-05-18

Review 7.  Role of Inflammation in Heart Failure.

Authors:  Lily F Shirazi; Joe Bissett; Francesco Romeo; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

Review 8.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

9.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

Review 10.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.